利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.031 秒)

    Methods of Modifying Eukaryotic Cells
    2.
    发明申请
    Methods of Modifying Eukaryotic Cells 审中-公开

    公开(公告)号：US20140041068A1

    公开(公告)日：2014-02-06

    申请号：US14046291

    申请日：2013-10-04

    申请人： ANDREW J. MURPHY ,  GEORGE D. YANCOPOULOS ,  MARGARET KAROW ,  LYNN MACDONALD ,  SEAN STEVENS

    发明人： ANDREW J. MURPHY ,  GEORGE D. YANCOPOULOS ,  MARGARET KAROW ,  LYNN MACDONALD ,  SEAN STEVENS

    IPC分类号： A01K67/027

    摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

    Methods of Modifying Eukaryotic Cells
    3.
    发明申请
    Methods of Modifying Eukaryotic Cells 审中-公开

    公开(公告)号：US20140033336A1

    公开(公告)日：2014-01-30

    申请号：US14046285

    申请日：2013-10-04

    申请人： ANDREW J. MURPHY ,  GEORGE D. YANCOPOULOS ,  MARGARET KAROW ,  LYNN MACDONALD ,  SEAN STEVENS

    发明人： ANDREW J. MURPHY ,  GEORGE D. YANCOPOULOS ,  MARGARET KAROW ,  LYNN MACDONALD ,  SEAN STEVENS

    IPC分类号： A01K67/027

    摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

    METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF)
    6.
    发明申请
    METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF) 审中-公开
    使用IL-1拮抗剂治疗家族中性粒细胞（FMF）的方法

    公开(公告)号：US20110311537A1

    公开(公告)日：2011-12-22

    申请号：US13222759

    申请日：2011-08-31

    申请人： SCOTT MELLIS ,  MARGARET KAROW ,  GEORGE D. YANCOPOULOS ,  JOANNE PAPADOPOULOS

    发明人： SCOTT MELLIS ,  MARGARET KAROW ,  GEORGE D. YANCOPOULOS ,  JOANNE PAPADOPOULOS

    IPC分类号： A61K39/395 ,  A61P29/00

    CPC分类号： C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    摘要： Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action of IL-1, thereby treating, inhibiting or ameliorating FMF. Also provided are methods of treating, inhibiting, or ameliorating FMF by administering a therapeutically effective amount of an IL-1 antagonist in combination with additional therapeutic agents, including IL-1-specific fusion proteins, TNF inhibitors, NSAIDs, steroids, and the like.

    摘要翻译： 提供了通过向有需要的受试者施用治疗有效量的白细胞介素1（IL-1）拮抗剂来治疗，抑制或改善家族性地中海热（FMF）的方法。 IL-1拮抗剂可以是抗体或其衍生物，其能够阻断或抑制IL-1的生物学作用，从而治疗，抑制或改善FMF。 还提供了通过将治疗有效量的IL-1拮抗剂与另外的治疗剂（包括IL-1特异性融合蛋白，TNF抑制剂，NSAID，类固醇等）组合施用来治疗，抑制或改善FMF的方法 。

    IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    8.
    发明申请
    IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF 有权
    IGF-1融合多肽及其治疗用途

    公开(公告)号：US20110020342A1

    公开(公告)日：2011-01-27

    申请号：US12894278

    申请日：2010-09-30

    申请人： DAVID J. GLASS ,  GEORGE D. YANCOPOULOS ,  THOMAS J. DALY ,  NICHOLAS J. PAPADOPOULOS

    发明人： DAVID J. GLASS ,  GEORGE D. YANCOPOULOS ,  THOMAS J. DALY ,  NICHOLAS J. PAPADOPOULOS

    IPC分类号： A61K39/395 ,  C07K19/00 ,  C07H21/04 ,  C12N15/63 ,  C12N1/21 ,  C12N1/19 ,  C12N5/10 ,  C12P21/00 ,  A61P21/00 ,  A61P3/10

    CPC分类号： C07K14/65 ,  A61K38/30 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/75

    摘要： A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.

    摘要翻译： 包含至少一种IGF1变体组分和融合组分（F）以及任选的信号序列的融合蛋白相对于天然IGF1或IGF2多肽表现出改进的稳定性。 融合组分（F）可以是多聚化组分，例如免疫球蛋白结构域，特别是IgG的Fc结构域或IgG的重链。 IGF1变体显示具有改善的能力，以增加受到恶病质，固定化，老化，慢性疾病，癌症，遗传性疾病，引起萎缩症等引起的肌肉萎缩的受试者的肌肉质量的增加。 IGF1变体在降低患有糖尿病或高血糖症的受试者中的血糖中也是有效的。